polydotin
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT01370720)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 3,4,5-trihydroxystilbene-3-beta-monoglucoside
- 3,4',5-trihydroxystilbene-3-β-d-glucoside
- 3,4',5-trihydroxystilbene-3-β-d-glucoside
- 3,4,5-tsg
- 3-hydroxy-5-(2-(4-hydroxyphenyl)ethenyl)phenyl-beta-d-glucoside
- 5,4'-dihydroxystilbene-3-o-beta-d-glcp
- piceid
- pieceid
- polydatin
- polydatin
- polydatin
- polydatin
- polydatin
- polydatin
- polydatin, (e)-isomer
- polydotin peceid
- resveratrol 3-o-beta-d-glucoside
- resveratrol-3-o-b-mono-d-glucoside
- resveratrol-3-o-b-mono-d-glucoside
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01780129 | Phase 2 | Feb 1, 2013 | Neptunus Pharmaceuticals Inc. |
| NCT01370720 | Phase 2 | Feb 1, 2010 | CM&D Pharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CM&D Pharma | For profit | 1 | 1 | 1 | 2010 |
| Neptunus Pharmaceuticals Inc. | For profit | 1 | 1 | 1 | 2013 |
2 organizations
Page 1 / 1